within Pharmacolibrary.Drugs.ATC.A;

model A10BJ03
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0005833333333333334,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.1,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BJ03</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lixisenatide is a once-daily injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) used to improve glycemic control in adults with type 2 diabetes mellitus. It enhances glucose-dependent insulin secretion and suppresses glucagon secretion. Lixisenatide is currently approved and marketed for clinical use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from healthy adult subjects, both sexes, under fasting conditions after subcutaneous administration.</p><h4>References</h4><ol><li><p>Petersen, AB, et al., &amp; Christensen, M (2013). Lixisenatide for the treatment of type 2 diabetes. <i>Drugs of today (Barcelona, Spain : 1998)</i> 49(9) 537–553. DOI:<a href=\"https://doi.org/10.1358/dot.2013.49.9.2020940\">10.1358/dot.2013.49.9.2020940</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24086950/\">https://pubmed.ncbi.nlm.nih.gov/24086950</a></p></li><li><p>Christensen, M, et al., &amp; Vilsboll, T (2009). Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. <i>IDrugs : the investigational drugs journal</i> 12(8) 503–513. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19629885/\">https://pubmed.ncbi.nlm.nih.gov/19629885</a></p></li><li><p>Gautier, T, et al., &amp; Breton, MD (2022). Modeling the Effect of Subcutaneous Lixisenatide on Glucoregulatory Endocrine Secretions and Gastric Emptying in Type 2 Diabetes to Simulate the Effect of iGlarLixi Administration Timing on Blood Sugar Profiles. <i>Journal of diabetes science and technology</i> 16(2) 428–433. DOI:<a href=\"https://doi.org/10.1177/19322968211015671\">10.1177/19322968211015671</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34013770/\">https://pubmed.ncbi.nlm.nih.gov/34013770</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BJ03;
